Akero elbows its way into a crowded NASH field, with $65M and a strategy for tackling a blockbuster market
Over the last few weeks we’ve been treated to a couple of stories about small biotechs which enjoyed a swift run-up in stock values after posting their beauty shots of clinical data for NASH drugs. NASH remains the big new disease target that is sucking up a lot of R&D attention at large and small biopharmas around the world, and investors are looking to ride one of the winning players to the promised land.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.